An Exploratory Study on the Use of Ivosidenib for the Precise Treatment of Advanced Biliary Tract Malignancies With IDH1 Mutations in the Later Line of Therapy.

NCT07282262 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

300

Enrollment

OTHER

Sponsor class

Conditions

Biliary Tract Cancer

Interventions

DRUG: Ivosidenib
DRUG: Lenvatinib
BIOLOGICAL: PD-1/PD-L1 inhibitor

Sponsor

Peking Union Medical College Hospital